NCT06092645View on ClinicalTrials.gov

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

October 1, 2024

Study Completion Date

October 31, 2025

Conditions
Bile Duct Adenocarcinoma
Interventions
DRUG

surufatinib plus cadonilimab

Surufatinib: 250mg , po,qd, d1-d21, every 3 weeks for a treatment cycle. Cadonilimab: 10mg/kg, iv, d1, every 3 weeks for a treatment cycle

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER